<p>
    Medications (Anti-rejection):
</p>
<p>
    <strong>Prednisone:</strong>
</p>
<p>
    Give Prednisone at the following schedule:
</p>
    <table class="table table-bordered">
        <tbody>
            <tr>
                <td>
                    POD1
                </td>
                <td>
                    Methylprednisolone 200mg IV
                </td>
            </tr>
            <tr>
                <td>
                    POD2
                </td>
                <td>
                    Methylprednisolone 160mg IV
                </td>
            </tr>
            <tr>
                <td>
                    POD3
                </td>
                <td>
                    Methylprednisolone 120mg IV
                </td>
            </tr>
            <tr>
                <td>
                    POD4
                </td>
                <td>
                    Methylprednisolone 80mg IV
                </td>
            </tr>
            <tr>
                <td>
                    POD5
                </td>
                <td>
                    Methylprednisolone 40mg IV
                </td>
            </tr>
            <tr>
                <td>
                    POD6 and beyond
                </td>
                <td>
                    <p>
                        Oral prednisone 20mg daily <span data-huuid="9700791460640309372">→</span> Continue for 2 weeks
                    </p>
                    <ul>
                        <li data-list-item-id="e99c58363fd34c9e1e924d52d3b39c06d">
                            Taper down to 15mg po daily for 2 weeks. 
                        </li>
                        <li data-list-item-id="ebd50a93a0e2e999a3c6886c2e49053a6">
                            Taper down to 10mg po daily for 2 weeks. 
                        </li>
                        <li data-list-item-id="ecb7356487329dde25c3b1b56e5c701ce">
                            Taper down to 5mg po daily for 2 weeks
                        </li>
                        <li data-list-item-id="e9b54c488cc4d9bc40ebc7d55a80efdbd">
                            Taper down to 5mg po every other day for 2 weeks then discontinue
                        </li>
                    </ul>
                </td>
            </tr>
        </tbody>
    </table>

<p>
    <strong>Basilixmab (Simulect)</strong>
</p>
<p>
    Indicated in the following: 
</p>
<ul>
    <li data-list-item-id="e39d974fac9ed30ec5958a6a1506d0bec">
        Baseline creatinine above 150 (EGFR 30-60)
    </li>
    <li data-list-item-id="ec0aa7e94d21f306f8b5d45e39907fd3b">
        Patients on HD pre-transplant
    </li>
    <li data-list-item-id="edb0d022f27acb1fd1fd7d7fb25319bc6">
        Patients who are expected to not be able to receive appropriate tacrolimus dose on a timely fashion (in patients with delirium, fragile and older than 70). 
    </li>
    <li data-list-item-id="ee91fbec03eeea929be5c9e6c1687e7b6">
        Dose: 20mg IV on POD 0 <span data-huuid="9700791460640309372">→</span> 20mg IV once on POD 4.
        <ul>
            <li data-list-item-id="ec2a1bf5052349c439ddf09c12efd6c62">
                Can be given every 2 weeks if unable to get patient on appropriate immunosuppression 
            </li>
        </ul>
    </li>
</ul>
<p>
    <strong>ATG (Alternative ot Basilixmad, given only if contraindication to Basilixmab)</strong>
</p>
<ul>
    <li data-list-item-id="ec0f3421fbdcab1fb2b1c1b2354a3dfad">
        Dose: 
        <ul>
            <li data-list-item-id="e06d2bd1193df423027f37290ae61ea27">
                Low risk patients (ABO compatible or first transplant): ATG 3-5 mg/kg over 5 days
            </li>
            <li data-list-item-id="e76a96e0da642bf492a272146ccda9076">
                High risk patients (ABO incompatible or re-transplant): ATG 5-7 mg/kg over 5 days. 
            </li>
        </ul>
    </li>
</ul>
<p>
    <strong>Tacrolimus (Prograf) – 1st line:</strong>
</p>
<ul>
    <li data-list-item-id="e58bc0aa8d1167dfab60e3e1e7fd8607e">
        All patients should receive 1-2 mg PO bid on POD1
        <ul>
            <li data-list-item-id="e174c671187c22a53d956da55bfe4f443">
                Consider 0.5mg bid if delirium, malnourished and patients with AKI or on HD
            </li>
            <li data-list-item-id="e5e5728b5257bbaa959abba1bff9fc97c">
                Consider 2-3mg bid if the patient is young or BMI above 35
            </li>
            <li data-list-item-id="e7eaf04d38a2b7eb26ec8916c94f124dc">
                Moderate dose Myfortic (180-360) patient should have dose reduced by 30%
            </li>
            <li data-list-item-id="e55ed6994a53bc8a1b6e563d6c15c09af">
                High dose Myfortic (540-720) patient should have dose reduced by 50%. 
            </li>
            <li data-list-item-id="e448f9a32b258d4c57189cb1b6d4b0cb0">
                Sublingual tacrolimus available (decrease dose by 20%)
            </li>
        </ul>
    </li>
    <li data-list-item-id="e43fbf57c346bcc66be2ca879de37953d">
        Advagraf (once daily dosing regimen) can be given for patients with coverage (increase dose by 25%) 
    </li>
</ul>
<p>
    Target Tac Levels:
</p>

    <figure class="table" style="width:100%;">
    <table class="ck-table-resized table-bordered">
        <colgroup><col style="width:9.92%;"><col style="width:8.75%;"><col style="width:29.44%;"><col style="width:18.36%;"><col style="width:22.6%;"><col style="width:10.93%;"></colgroup>
        <tbody>
            <tr class="table-secondary">
                <td>
                    Time
                </td>
                <td>
                    Normal
                </td>
                <td>
                        Age &gt;65/Frail/ Mild neurological side effects/CKD/Good myfortic dose 
                </td>
                <td>
                    PSC/AIH/PBC/ Previous cellular rejection 
                </td>
                <td>
                    Both mild neurological side effects AND high creatinine 
                </td>
                <td>
                    PTLD or recurrent HCC 
                </td>
            </tr>
            <tr>
                <td>
                    Less than 3 months 
                </td>
                <td>
                    8-10 
                </td>
                <td>
                    6-8 
                </td>
                <td>
                    10-12 
                </td>
                <td>
                    5-6
                </td>
                <td>
                    4-6 
                </td>
            </tr>
            <tr>
                <td>
                    3-12 months 
                </td>
                <td>
                    6-8 
                </td>
                <td>
                    5-6
                </td>
                <td>
                    8-10
                </td>
                <td>
                    4-5
                </td>
                <td>
                    4-5
                </td>
            </tr>
            <tr>
                <td>
                    12-24 months 
                </td>
                <td>
                    4-6 
                </td>
                <td>
                    2-4 
                </td>
                <td>
                    6-8 
                </td>
                <td>
                    2-4
                </td>
                <td>
                    2-4 
                </td>
            </tr>
            <tr>
                <td>
                    After 2 years 
                </td>
                <td>
                    2-4 
                </td>
                <td>
                    Above 2 
                </td>
                <td>
                    4-6 
                </td>
                <td>
                    Above 2 
                </td>
                <td>
                    Above 2 
                </td>
            </tr>
        </tbody>
    </table>
</figure>

<p>
    <strong>Cyclosporine (APO-cyclosporine) – 2nd line:</strong>
</p>
<ul>
    <li data-list-item-id="e359e72e078d8933a561d0224b2f09b6b">
        Indicated for patients with Tacrolimus allergy or unmanageable CNS side-effects from Tacrolimus
    </li>
    <li data-list-item-id="e6d252945cda2e39bde44caed50e51726">
        Dose: 50-100 mg po bid on POD1
        <ul>
            <li data-list-item-id="ea1d9ae3c64110dd9687591c6a5dcb973">
                Consider 50 mg bid if delirium, malnourished and patients with AKI or on HD
            </li>
            <li data-list-item-id="e9bf7395eabdfe49eb1568ba265b15915">
                Consider 200 mg bid if the patient is young or BMI above 35
            </li>
            <li data-list-item-id="e51e24f5995c23962ebdb20a6e9113868">
                Moderate dose Myfortic (180-360) patient should have dose reduced by 30%
            </li>
            <li data-list-item-id="e8f2073bb0be2d23104deb4eb4b28913d">
                High dose Myfortic (540-720) patient should have dose reduced by 50%. &nbsp;
            </li>
        </ul>
    </li>
</ul>
<p>
    Target C2 Levels:
</p>

<figure class="table" style="width:100%;">
    <table class="ck-table-resized table-bordered">
        <colgroup><col style="width:9.93%;"><col style="width:10.66%;"><col style="width:27.47%;"><col style="width:18.38%;"><col style="width:22.62%;"><col style="width:10.94%;"></colgroup>
        <tbody>
            <tr class="table-secondary">
                <td>
                    Time
                </td>
                <td>
                    Normal
                </td>
                <td>
                    Age &gt;65/Frail/ Mild neurological side effects/CKD/Good myfortic dose 
                </td>
                <td>
                    PSC/AIH/PBC/ Previous cellular rejection
                </td>
                <td>
                    Both mild neurological side effects AND high creatinine 
                </td>
                <td>
                    PTLD or recurrent HCC 
                </td>
            </tr>
            <tr>
                <td>
                    Less than 3 months 
                </td>
                <td>
                    800-1000 
                </td>
                <td>
                    600-800 
                </td>
                <td>
                    1000-1200
                </td>
                <td>
                    500-600
                </td>
                <td>
                    400-600
                </td>
            </tr>
            <tr>
                <td>
                    3-12 months 
                </td>
                <td>
                    600-800
                </td>
                <td>
                    500-600
                </td>
                <td>
                    800-1000
                </td>
                <td>
                    400-500
                </td>
                <td>
                    400-500
                </td>
            </tr>
            <tr>
                <td>
                    12-24 months 
                </td>
                <td>
                    400-600
                </td>
                <td>
                    200-400
                </td>
                <td>
                    600-800 
                </td>
                <td>
                    200-400
                </td>
                <td>
                    200-400
                </td>
            </tr>
            <tr>
                <td>
                    After 2 years 
                </td>
                <td>
                    200-400
                </td>
                <td>
                    Above 200
                </td>
                <td>
                    400-600
                </td>
                <td>
                    Above 200 
                </td>
                <td>
                    Above 200
                </td>
            </tr>
        </tbody>
    </table>
</figure>

<p>
    <strong>Sirolimus (Rapamune) – 3rd Line:</strong>
</p>
<ul>
    <li data-list-item-id="e774081a7c7686571ada0f18b9a381fe3">
        Indicated for the following patients:
        <ul>
            <li data-list-item-id="e12770bdeb3d6fd49d9631c57b4c36ab0">
                Contraindication from Tac or C2 (i.e., high creatinine, CNS side effects)
            </li>
            <li data-list-item-id="e2fa84b5d901aada8269a30999ac0e872">
                Private Coverage + Cancer treatment with liver transplant &nbsp;
            </li>
            <li data-list-item-id="ef551cc13e9f3616163110da83df7f524">
                Prive Coverage + HCC RETREAT score &gt;4
            </li>
        </ul>
    </li>
    <li data-list-item-id="ea2e9e1e64ba5c09f6657babcff905508">
        Dose: 2-5 mg po bid on POD1
        <ul>
            <li data-list-item-id="e51f5e65a1588b1568b425d3de0364736">
                DO NOT USE during first month post-transplant (Risk of hepatic artery stenosis) &nbsp;
            </li>
            <li data-list-item-id="e39d267e106f4d0aa8a2205ca7eca1058">
                Moderate dose Myfortic (180-360) patient should have dose reduced by 30%
            </li>
            <li data-list-item-id="e98c6cf10de6f6e99385685a5dace8a2a">
                High dose Myfortic (540-720) patient should have dose reduced by 50%. &nbsp;
            </li>
        </ul>
    </li>
</ul>
<p>
    Target Sirolimus Levels:&nbsp;
</p>

<figure class="table">
    <table class=" table-bordered">
        <tbody>
            <tr class="table-secondary">
                <td>
                    Time &nbsp;
                </td>
                <td>
                    Normal &nbsp;
                </td>
                <td>
                    PSC/AIH/PBC/Previous cellular rejection &nbsp;
                </td>
                <td>
                    Good dose of Myfortic &nbsp;
                </td>
            </tr>
            <tr>
                <td>
                    1-3 months
                </td>
                <td>
                    6-10  
                </td>
                <td>
                    10 
                </td>
                <td>
                    5-6 
                </td>
            </tr>
            <tr>
                <td>
                    After 3-12 months 
                </td>
                <td>
                    3-8 
                </td>
                <td>
                    8
                </td>
                <td>
                    3-5
                </td>
            </tr>
            <tr>
                <td>
                    After 1 year
                </td>
                <td>
                    Above 2 
                </td>
                <td>
                    3-6 
                </td>
                <td>
                    Above 2
                </td>
            </tr>
        </tbody>
    </table>
</figure>
<p>
    <strong>Myfortic:</strong>
</p>
<ul>
    <li data-list-item-id="e3f5daeca3494f89b8c4dbf84dca400bb">
         Indicated for the following patients:
        <ul>
            <li data-list-item-id="e1a009440ff556a9430f84c23fc99bc47">
                 Unable to reach target from Tac/C2 or present with mild CKD/CNS side effects from Tac/C2
            </li>
            <li data-list-item-id="e06b7e466c5b892dcacebcfe3a19de9c8">
                 PSC, PBC, AIH, re-transplant patients
            </li>
            <li data-list-item-id="ecbce46c15a5a27dd89c3ea33d12cb6a8">
                 High risk of rejection patients (CMV mismatch, young females)
            </li>
        </ul>
    </li>
    <li data-list-item-id="e5dfbfafc8619634447d4dc68e07cb5bf">
         Dose: &nbsp;Start at 180 mg po bid on POD2-5 (dose 180/360/540/720 mg)
        <ul>
            <li data-list-item-id="e063018d950fcdb6bc0892d4a273b3338">
                 For NG Tube patients use Cellcept (dose at 250/500/750 mg)
            </li>
            <li data-list-item-id="e91a255fa6e359ed10fd18ba1726d2771">
                 IV Dose same as oral
            </li>
            <li data-list-item-id="efeab0aeb3159866b66c724afbdcf7ca3">
                 Hold if following:
                <ul>
                    <li data-list-item-id="e0dfd0b060b6de47549d61a82c7b16399">
                         Active infection &nbsp;
                    </li>
                    <li data-list-item-id="e1a613c974eecd266ff590c5cb18ab93e">
                         WBC &lt; 2 <span data-huuid="9700791460640309372">→</span> restart when &gt; 3 and Hb above 80
                    </li>
                    <li data-list-item-id="ecdfdc08c2f59fb9a10ab2bb7405cf1bf">
                         Platelets &lt; 40 <span data-huuid="9700791460640309372">→</span> restart when &gt; 50 and Hb above 80
                    </li>
                </ul>
            </li>
        </ul>
    </li>
</ul>
<p>
    <strong>Azanthioprine (Imuran) – Alternative to Myfortic:</strong>
</p>
<ul>
    <li data-list-item-id="e0fe0e82b0ba2648767acb1058d6094a5">
         Indicated for patients intolerant of myfortic (i.e., GI side effects or allergy)
    </li>
    <li data-list-item-id="e80c3b37bbd54485310d820cd20f3bfdf">
         TMPT testing must be done before use
    </li>
    <li data-list-item-id="e60b5010305660a7af1a0bdbd94697e83">
         Dose: 1-2mg/kg per day (25/50/75/100mg po daily)
        <ul>
            <li data-list-item-id="e98cf7694ca5845da6161c05acf5b034e">
                 IV Dose same as oral
            </li>
            <li data-list-item-id="ed4c417e73a9eb482f74d8c1930d9999f">
                 Hold if following:
                <ul>
                    <li data-list-item-id="e3e8e962059ec180caec04be4b3fb0aca">
                         Active infection &nbsp;
                    </li>
                    <li data-list-item-id="e2158f88c9905371b82fb89c2d830e942">
                         WBC &lt; 2 <span data-huuid="9700791460640309372">→</span> restart when &gt; 3 and Hb above 80
                    </li>
                    <li data-list-item-id="efbc14ac2c3df9b4ef6b29a7d6c0b23f0">
                         Platelets &lt; 40 <span data-huuid="9700791460640309372">→</span> restart when &gt; 60 and Hb above 80
                    </li>
                </ul>
            </li>
        </ul>
    </li>
    <li data-list-item-id="e02b714976c22a9b09494199316bf673f">
         Start 0.5mg/kg per day if WBC is 2-3 or platelets is 40-60.&nbsp;
    </li>
</ul>